Literature DB >> 19815380

Continued global left ventricular remodeling is not the sole mechanism responsible for the late recurrence of ischemic mitral regurgitation after restrictive annuloplasty.

Julien Magne1, Philippe Pibarot, Jean G Dumesnil, Mario Sénéchal.   

Abstract

BACKGROUND: Recurrence of ischemic mitral regurgitation (MR) late after mitral valve annuloplasty (MVA) is generally believed to be due to continued left ventricular (LV) remodeling. The aim of this study was to determine if other mechanisms could be involved in MR recurrence. METHODS AND
RESULTS: Preoperative (10 +/- 11 days), early postoperative (6 +/- 4 days), and late postoperative (1.5 +/- 0.6 years) transthoracic echocardiograms of 26 patients (68 +/- 7 years, 23 male [88%]) who underwent restrictive MVA and coronary artery bypass graft surgery were reviewed. Mitral valve geometry and MR severity were assessed using anterior leaflet and posterior leaflet angles and the anterior leaflet concavity area, defined as the area enclosed between the AL and a line connecting the tip of the leaflet and its basal insertion at the annulus. Recurrent MR (vena contracta > 3 mm) was observed in 10 patients (38.5%). Among the 10 patients with recurrent MR, 5 had significant late postoperative increase in LV end-systolic (preoperative: 66 +/- 27 mL; early postoperative: 61 +/- 11 mL; late postoperative: 89 +/- 30 mL, P = .04) and end-diastolic (preoperative: 122 +/- 39 mL; early postoperative: 108 +/- 22 mL; late postoperative: 139 +/- 39 mL, P = .04) volumes and PL angle (early postoperative: 65 +/- 12 degrees; late postoperative: 77 +/- 8 degrees, P = .04), suggesting that recurrent MR is related to continued adverse LV remodeling and ensuing worsening of leaflet tethering. However, in the remaining 5 patients with recurrent MR, there was no significant change in LV end-systolic and end-diastolic volumes, but there was a significant increase in anterior leaflet concavity area (early postoperative: 6 +/- 11 mm(2); late postoperative: 50 +/- 3 mm(2), P = .012).
CONCLUSION: Although recurrent MR is often associated with continued adverse LV remodeling after restrictive MVA, this mechanism fails to explain all recurrences. In the absence of LV dilatation, recurrent MR might be explained by localized LV remodeling in the vicinity of papillary muscles resulting in increased AL tethering at the bending point.

Entities:  

Mesh:

Year:  2009        PMID: 19815380     DOI: 10.1016/j.echo.2009.07.029

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  10 in total

Review 1.  Surgical approach to mitral regurgitation in chronic heart failure: when is it an option?

Authors:  Juan A Crestanello
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 2.  Surgical Treatment of Ischemic Mitral Regurgitation: Valve Repair Versus Replacement.

Authors:  Abhishek Sharma; Sahil Agrawal; Sunny Goel; Jeffrey S Borer
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

Review 3.  Biomechanics raises solution to avoid geometric mitral valve configuration abnormalities in ischemic mitral regurgitation.

Authors:  Francesco Nappi; Cristiano Spadaccio; Christos G Mihos; Massimiliano Fraldi
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

4.  Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation.

Authors:  Irving L Kron; Judy Hung; Jessica R Overbey; Denis Bouchard; Annetine C Gelijns; Alan J Moskowitz; Pierre Voisine; Patrick T O'Gara; Michael Argenziano; Robert E Michler; Marc Gillinov; John D Puskas; James S Gammie; Michael J Mack; Peter K Smith; Chittoor Sai-Sudhakar; Timothy J Gardner; Gorav Ailawadi; Xin Zeng; Karen O'Sullivan; Michael K Parides; Roger Swayze; Vinod Thourani; Eric A Rose; Louis P Perrault; Michael A Acker
Journal:  J Thorac Cardiovasc Surg       Date:  2014-11-06       Impact factor: 5.209

5.  Ex Vivo Model of Ischemic Mitral Regurgitation and Analysis of Adjunctive Papillary Muscle Repair.

Authors:  Annabel M Imbrie-Moore; Yuanjia Zhu; Tabitha Bandy-Vizcaino; Matthew H Park; Robert J Wilkerson; Y Joseph Woo
Journal:  Ann Biomed Eng       Date:  2021-11-03       Impact factor: 4.219

6.  Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.

Authors:  Daniel Goldstein; Alan J Moskowitz; Annetine C Gelijns; Gorav Ailawadi; Michael K Parides; Louis P Perrault; Judy W Hung; Pierre Voisine; Francois Dagenais; A Marc Gillinov; Vinod Thourani; Michael Argenziano; James S Gammie; Michael Mack; Philippe Demers; Pavan Atluri; Eric A Rose; Karen O'Sullivan; Deborah L Williams; Emilia Bagiella; Robert E Michler; Richard D Weisel; Marissa A Miller; Nancy L Geller; Wendy C Taddei-Peters; Peter K Smith; Ellen Moquete; Jessica R Overbey; Irving L Kron; Patrick T O'Gara; Michael A Acker
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

7.  Echocardiographic assessment of ischemic mitral regurgitation.

Authors:  David M Dudzinski; Judy Hung
Journal:  Cardiovasc Ultrasound       Date:  2014-11-21       Impact factor: 2.062

8.  Echocardiographic Assessment of Ischaemic Mitral Regurgitation, Mechanism, Severity, Impact on Treatment Strategy and Long Term Outcome.

Authors:  Nabil Naser; Alen Dzubur; Zumreta Kusljugic; Katarina Kovacevic; Mehmed Kulic; Sekib Sokolovic; Ibrahim Terzic; Ilirijana Haxihibeqiri-Karabdic; Zorica Hondo; Snjezana Brdzanovic; Sanja Miseljic
Journal:  Acta Inform Med       Date:  2016-06-04

9.  Dynamic changes in the ischemic mitral annulus: Implications for ring sizing.

Authors:  Khurram Owais; Mario Montealegre-Gallegos; Jelliffe Jeganathan; Robina Matyal; Kamal R Khabbaz; Feroze Mahmood
Journal:  Ann Card Anaesth       Date:  2016 Jan-Mar

10.  Exploring the Operative Strategy for Secondary Mitral Regurgitation: A Systematic Review.

Authors:  Francesco Nappi; Sanjeet Singh Avtaar Singh; Francesca Bellomo; Pierluigi Nappi; Camilla Chello; Adelaide Iervolino; Massimo Chello
Journal:  Biomed Res Int       Date:  2021-06-22       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.